Koninklijke Philips (PHIA) Q3 2025 earnings summary

Executive summary

• Q3 2025 saw 8% growth in comparable order intake and 3% comparable sales growth, with all business segments contributing and Personal Health showing particularly strong performance.

• Margin expansion was achieved, with adjusted EBITA/EBITDA margin up 50 basis points to 12.3%, driven by innovation, productivity, and disciplined execution despite tariff impacts.

• Free cash flow rose to EUR 172 million, with strong operational execution and productivity gains supporting a positive outlook.

• Net income increased to EUR 187 million, supported by higher earnings and lower financial expenses.

• The margin outlook for full-year 2025 is now expected at the upper end of the previously guided range.

Financial highlights

• Group sales reached EUR 4.3 billion, up 3.3% year-over-year in comparable terms.

• Adjusted EBITA margin increased to 12.3%, up 50 basis points year-over-year.

• Net income rose to EUR 187 million, mainly due to higher earnings and lower financial expenses.

• Free cash flow for Q3 was EUR 172 million, a significant year-over-year improvement.

• Adjusted diluted EPS from continued operations was EUR 0.36, up 13% year-over-year.

Outlook and guidance

• Full-year 2025 guidance reiterated: comparable sales growth of 1–3%, adjusted EBITA margin of 11.3–11.8% (now expected at the upper end), and free cash flow of EUR 0.2–0.4 billion.

• Tariff impact for 2025 anticipated at EUR 150–200 million after mitigation.

• Restructuring costs expected at ~120 bps for 2025, down from 150 bps last year.

• Outlook excludes potential wider economic impacts and ongoing Respironics-related proceedings.